Table 4. Mean values (M ± SD) of corpuscular values in piperazine treated group (n = 20) and D_oraTG (n = 20).

Groups	Follow up period	MCV (fL) (46–67)1	MCH (pg) (16–23)1	MCHC (g/l) (320–360)1
PipTG	Day 0a	67.41 ± 14.17	22.43 ± 5.09	331.88 ± 11.46
	Day 7	61.58 ± 9.10	18.86 ± 1.83b	308.23 ± 18.07b
	Day 14	58.84 ± 6.82	19.52 ± 3.40	331.08 ± 31.1
	Day 21	63.04 ± 10.00	18.81 ± 3.17	300.36 ± 37.81b
	Day 28	54.13 ± 6.89	16.22 ± 1.88b	302.78 ± 42.33
DoraTG	Day 0a	77.72 ± 19.73	24.65 ± 6.20	318.95 ± 35.19
	Day 7	68.32 ± 8.43	19.94 ± 2.48c	292.53 ± 20.63
	Day 14	60.30 ± 5.02c	18.45 ± 1.58c	306.36 ± 18.21
	Day 21	54.89 ± 3.60c	16.75 ± 1.64c	305.7 ± 29.79
	Day 28	56.62 ± 7.19c	17.31 ± 2.22c	307.26 ± 32.61

Reference values according to Grondin and Dewitt (2010).

P_ipTG = piperazine treated group; D_oraTG = doramectin treated group; MCV = Mean corpuscular volume; MCH = Mean corpuscular haemoglobin; MCHC = Mean corpuscular haemoglobin concentration.

^aTreatment day.

^bSignificant when the values at each sampling day (7, 14, 21 or 28) compared with the value day 0 in P_ipTG (p < 0.05).

^cSignificant when the values at each sampling day (7, 14, 21 or 28) compared with the value at day 0 in D_oraTG (p < 0.05).